EcoDrugPlus

Tubulin, Beta 2a Class Iia

Ensembl ID : ENSOMYG00000001436
Gene Symbol: TUBB2
1 Cross references
301 Possible Orthologues:

Tubulin, Beta 2a Class Iia

Ensembl ID : ENSOMYG00000031371
Gene Symbol: TUBB2
1 Cross references
299 Possible Orthologues:

Tubulin, Beta 5

Ensembl ID : ENSOMYG00000074503
Gene Symbol: TUBB5
1 Cross references
217 Possible Orthologues:

Tumor Protein P53

Ensembl ID : ENSOMYG00000023603
Gene Symbol: TP53
2 Cross references
160 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSOMYG00000040409
Gene Symbol: TYR
1 Cross references
201 Possible Orthologues:

Tyrosine Kinase 2

Ensembl ID : ENSOMYG00000042593
Gene Symbol: TYK2
1 Cross references
190 Possible Orthologues:

Urotensin 2 Receptor

Ensembl ID : ENSOMYG00000022217
Gene Symbol: UTS2R
1 Cross references
97 Possible Orthologues:

V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog

Ensembl ID : ENSOMYG00000006134
Gene Symbol: KRAS
1 Cross references
201 Possible Orthologues:

V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog

Ensembl ID : ENSOMYG00000040879
Gene Symbol: KRAS
1 Cross references
202 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 2

Ensembl ID : ENSOMYG00000041208
Gene Symbol: AKT2
1 Cross references
190 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 3a

Ensembl ID : ENSOMYG00000044608
Gene Symbol: AKT3A
2 Cross references
203 Possible Orthologues:

V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A

Ensembl ID : ENSOMYG00000031656
Gene Symbol: RELA
1 Cross references
194 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).